SG11202111809XA - Compositions and methods for use of cannabinoids for neuroprotection - Google Patents

Compositions and methods for use of cannabinoids for neuroprotection

Info

Publication number
SG11202111809XA
SG11202111809XA SG11202111809XA SG11202111809XA SG11202111809XA SG 11202111809X A SG11202111809X A SG 11202111809XA SG 11202111809X A SG11202111809X A SG 11202111809XA SG 11202111809X A SG11202111809X A SG 11202111809XA SG 11202111809X A SG11202111809X A SG 11202111809XA
Authority
SG
Singapore
Prior art keywords
cannabinoids
neuroprotection
compositions
methods
Prior art date
Application number
SG11202111809XA
Other languages
English (en)
Inventor
Eric Hsu
Ujendra Kumar
Rishi Kumar Somvanshi
Shenglong Zou
Original Assignee
Inmed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmed Pharmaceuticals Inc filed Critical Inmed Pharmaceuticals Inc
Publication of SG11202111809XA publication Critical patent/SG11202111809XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202111809XA 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection SG11202111809XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838216P 2019-04-24 2019-04-24
PCT/CA2020/050547 WO2020215164A1 (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Publications (1)

Publication Number Publication Date
SG11202111809XA true SG11202111809XA (en) 2021-11-29

Family

ID=72940570

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111809XA SG11202111809XA (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Country Status (11)

Country Link
US (1) US20230043428A1 (es)
EP (1) EP3958856A4 (es)
JP (1) JP2022530471A (es)
KR (1) KR20220080045A (es)
CN (1) CN114007603A (es)
AU (1) AU2020261515A1 (es)
CA (1) CA3134764A1 (es)
IL (1) IL287536A (es)
MX (1) MX2021012960A (es)
SG (1) SG11202111809XA (es)
WO (1) WO2020215164A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006404A (zh) * 2022-08-09 2022-09-06 昆药集团股份有限公司 一种具有视神经保护功效的药物组合物及其应用
WO2024091653A1 (en) * 2022-10-27 2024-05-02 Kemin Industries, Inc. Use of a spearmint extract for retina neurotrophism

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3261629A4 (en) * 2015-02-27 2018-12-05 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
US20170266153A1 (en) * 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
BR112017018316A2 (pt) * 2015-02-27 2018-04-17 Ebbu Llc composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
EP3278100B1 (en) * 2015-03-28 2023-06-14 Tecan SP, Inc. Methods and uses comprising solid phase extraction, derivatization with crown ethers, and mass spectrometry
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Formulations of dilutable cannabinoids and processes for their preparation
CN109963595B (zh) * 2016-10-11 2023-02-03 Gbs全球生物制药公司 用于治疗神经退行性疾病的含有大麻素的复合混合物
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
AU2018266262B2 (en) * 2017-05-08 2022-10-06 Inmed Pharmaceuticals Inc. Ocular drug delivery formulation
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling

Also Published As

Publication number Publication date
WO2020215164A1 (en) 2020-10-29
AU2020261515A1 (en) 2021-11-18
IL287536A (en) 2021-12-01
JP2022530471A (ja) 2022-06-29
MX2021012960A (es) 2022-01-04
US20230043428A1 (en) 2023-02-09
CA3134764A1 (en) 2020-10-29
EP3958856A4 (en) 2023-01-25
CN114007603A (zh) 2022-02-01
KR20220080045A (ko) 2022-06-14
EP3958856A1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
GB2597163B (en) Cannabinoid compositions and methods of using
EP3775203A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
EP3704239A4 (en) CASZ COMPOSITIONS AND METHOD OF USE
EP3790596A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
EP3576782A4 (en) COMPOSITIONS OF RECOMBINATION PRODUCT-PEPTIDE AND THEIR METHODS OF USE
EP3704254A4 (en) CAS12C COMPOSITIONS AND METHOD OF USE
EP3893917A4 (en) IL-15 COMPOSITIONS AND METHODS OF USE THEREOF
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Preparations and methods of use
EP3600372A4 (en) SYNTHEKIN COMPOSITIONS AND METHODS OF USE
GB2597170B (en) Diluents for compositions of cannabinoids and uses thereof
EP3551747A4 (en) COMPOSITIONS AND METHODS FOR IN VITRO MATURING OF OOCYTES
GB202105087D0 (en) Microbial compositions and methods of use
IL287536A (en) Compositions and methods of using cannabinoids for neuroprotection
EP3606493A4 (en) DENTAL CEMENT COMPOSITIONS AND METHOD OF USE
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
IL283850A (en) Cannabis compounds and methods
EP3731841A4 (en) CRYOPERVATIVE COMPOSITIONS AND METHOD OF USING THEREOF
SG11202011041YA (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
EP3285755A4 (en) Compositions and methods for neuroprotection and treatment of neurodegeneration
IL283950A (en) Methods and compositions for creating cannabinoids
EP3843555A4 (en) ANTHOCYANE DYE COMPOSITIONS AND METHODS OF USE THEREOF
EP3426238A4 (en) CURCUMIN-BASED COMPOSITIONS & METHODS OF USE
EP3920904A4 (en) COMPOSITIONS CONTAINING CANNABINOIDS AND METHODS OF USE THEREOF
EP4054514A4 (en) COMPOSITIONS CONTAINING FENCHOLES AND METHOD OF USE